Argenx
ARGX
#475
Rank
NZ$91.66 B
Marketcap
NZ$1,458
Share price
-11.83%
Change (1 day)
4.96%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Half-year Reports

Thumbnail Argenx
 Half-year Report 2026-h1

Half-year Report 2026-h1

Language: English

View Half-year Report
Thumbnail Argenx
 Half-year Report 2025-h1

Half-year Report 2025-h1

Language: English

View Half-year Report
Thumbnail Argenx
 Half-year Report 2024-h1

Half-year Report 2024-h1

Language: English

View Half-year Report
Thumbnail Argenx
 Half-year Report 2023-h1

Half-year Report 2023-h1

Language: English

View Half-year Report
Thumbnail Argenx
 Half-year Report 2022-h1

Half-year Report 2022-h1

Language: English

View Half-year Report
Thumbnail Argenx
 Half-year Report 2021-h1

Half-year Report 2021-h1

Language: English

View Half-year Report
Thumbnail Argenx
 Half-year Report 2020-h1

Half-year Report 2020-h1

Language: English

View Half-year Report
Thumbnail Argenx
 Half-year Report 2019-h1

Half-year Report 2019-h1

Language: English

View Half-year Report
Thumbnail Argenx
 Half-year Report 2018-h1

Half-year Report 2018-h1

Language: English

View Half-year Report
Thumbnail Argenx
 Half-year Report 2017-h1

Half-year Report 2017-h1

Language: English

View Half-year Report
Thumbnail Argenx
 Half-year Report 2016-h1

Half-year Report 2016-h1

Language: English

View Half-year Report
Thumbnail Argenx
 Half-year Report 2015-h1

Half-year Report 2015-h1

Language: English

View Half-year Report
Thumbnail Argenx
 Half-year Report 2014-h1

Half-year Report 2014-h1

Language: English

View Half-year Report